MedTrace Logo

Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.

NCT06126003 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 2

Last updated 2024-08-02

No results posted yet for this study

Summary

The purpose of this research study is to collect samples of blood and stool and analyse primary tumor from participants with breast cancer to see how the bacteria in the body affect cancer and how well it responds to treatment. By comparing samples and data from multiple participants with breast cancer, it may be possible to identify how a person's gut health and tumor microenvironment affects how they respond to certain cancer treatments.

Conditions

Interventions

OTHER

Observation

No Intervention

Sponsors & Collaborators

  • Tempus AI

    collaborator INDUSTRY

  • BioCorteX Inc

    lead INDUSTRY

Principal Investigators

  • Nik Sharma, PhD · BioCorteX Inc

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2024-07-31
Completion
2024-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06126003 on ClinicalTrials.gov